A Phase I/II Open‐Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors

DOI: 10.1634/theoncologist.2019-0284

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text